AKL Therapeutics is a pharmaceutical company changing the way drugs are developed by seeking inspiration from nature to combat some of the biggest challenges facing modern medicine today.

We are committed to transforming patient’s lives through pioneering innovation. We begin by identifying secondary metabolites of plant origin, with proven efficacy and safety. These metabolites are then synthesized before undergoing standard pharmaceutical clinical development. This innovative approach greatly increases the chances of success, while reducing the risk of side effects.

Formal human clinical trials are currently underway assessing the safety and efficacy of an investigational oral therapy, ‘APPA’ in the treatment of osteoarthritis, a common and devastating disease with limited treatment options and no cure. APPA is also being evaluated in other inflammatory diseases and other molecules are also under investigation.

AKL Research & Development Ltd, trading as AKL Therapeutics Ltd, welcomes enquiries from potential investors and partners as we continue the development and commercialisation process.